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Abstract
Background: Calcium (Ca)- magnesium (Mg) imbalance is implicated in prostate cancer. Ca/Mg ratio increases or
decreases with proliferation or apoptosis, respectively. The study examined whether this Ca/Mg imbalance exists in
BPH patients and the effect of a phytotherapeutic drug on the Ca/Mg ratio.
Methods: Thirty (30) BPH patients who used the ethanolic root extract of Croton membranaceus (60 mg/day) for
3 months were examined for serum Ca, Mg, phosphate, parathyroid hormone (PTH), vitamin D, prostate specific
antigen (PSA) levels and renal function tests (RFT) before (BT) and after treatment (AT) alongside thirty (30) controls.
Twenty (20) trace element including Mg and Ca were determined in the drug by neutron activation analysis (NAA).
Results: RFT, PTH and vitamin D for BT, AT and controls (C) were normal. Mean PSA was 1.0 ± 0.64 (C), 27.9 ± 19.0
(BT) and 16.2 ± 11.8 ng/mL (AT) (p = 0.002). Mg, Ca/Mg ratio BT, AT and control were significantly different (p = 0.
0001, respectively). After treatment, Mg and Ca/Mg ratio were not different from controls. The prevalence of Ca/Mg
imbalance was 80% (BT), 13.3% (AT) and 3.3% (control group).
Conclusion: Ca/Mg ratio imbalance is associated with BPH. This has previously not been demonstrated. The
imbalance was significantly corrected after treatment with the phytotherapeutic drug.
Keywords: Calcium, Magnesium, Benign prostatic hyperplasia, Croton membranaceus
Background
Epidemiological studies of a cohort in Taiwan associated
drinking water Ca and Mg levels, to prostate cancer
(PCa) deaths. The authors concluded that Mg from the
drinking water or other dietary sources was protective
against prostate cancer [1]. Major trace elements such as
cadmium (Cd), nickel (Ni), zinc (Zn), copper (Cu), iron
(Fe), magnesium (Mg) and calcium (Ca) have previously
been identified in benign and malignant prostate sam-
ples. The concentrations of Ca and Mg have been found
to be significantly higher in the malignant prostate com-
pared to the benign among other metals [2]. X-ray
microanalysis on freeze-dried cryosections have been
used to demonstrate that Ca in secretory vessels is sev-
eral folds higher than Mg or Zn, buttressing the fact that
Ca is the major prostate acinar cell cation [3]. Further-
more, within the cytoplasm a positive correlation be-
tween Ca and Mg as well as Ca and Zn in hyperplastic
and normal glands has been demonstrated. Additionally,
increasing intranuclei Ca with advancing age has been
observed and is believed to have pathologic significance
in prostate growth disorders [3]. At the cellular level
studies strongly suggest the presence of Ca and Mg im-
balance in PCa cases [4].
Elevated extracellular calcium is thought to prevent
apoptosis via the Ca-sensing receptor [5]. Serum Mg
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levels of PCa patients when examined revealed a signifi-
cantly high Ca/Mg ratio. This was accounted for by an
equally significant lower Mg level. The odds indicated that
an elevated Ca/Mg ratio was associated with the increased
risk of high-grade PCa. On the other hand, elevated Mg
was significantly associated with a lower risk. However,
serum levels of Ca alone were not associated with PCa
and Ca/Mg levels were also not associated with BPH [6].
The Ca/Mg ratio has been implicated in proliferation of
prostate cancer cells compared to controls [4]. Ca2+ sig-
naling is therefore important in regulating other physio-
logical functions such as cell proliferation and
differentiation in conjunction with Mg [6–10].
Mg upon mitotic stimulation can initiate cell prolifera-
tion by activating Mg2+ influx and increasing intracellular
Mg2+ [11, 12]. Because both Ca and Mg are able to oper-
ate in a similar mechanism the efflux of both extracellular
metals needs tight control. An increase in cytosolic Ca2+
for example regulates apoptosis [13, 14]. At the extracellu-
lar level, an increase in Ca2+ or a decrease in extracellular
Mg2+ further increased Ca2+ influx. The efflux control of
Ca and Mg is regulated by a melastatin-like transient re-
ceptor potential (TRPM). These are a diverse group of
voltage-independent Ca2+-permeable cation channels
present in mammalian cells. TRPM6/7 gene mutations
have been demonstrated in hereditary hypomagnesaemia
caused by Mg2+ reabsorption impairment [15]. Addition-
ally, other studies have shown Mg2+ entry preference over
Ca2+. However, in the absence of Mg2+, the channels are
able to conduct Ca2+ currents. Therefore, an increase in
extracellular Ca2+ or a decrease in extracellular Mg2+ in-
creases Ca2+ influx. Additionally, the subsequent increase
in the Ca2+/Mg2+ ratio and TRPM7 expression has been
demonstrated in age-matched prostate cancer patients.
Therefore, an increase in the serum Ca2+/Mg2+ ratio will
increase Ca2+ entry by the activation of TRPM7 channels,
which eventually leads to increased cell proliferation and
cancer formation [4].
Current literature has provided evidence of the Ca/Mg
hemostasis and its involvement in cell proliferation as
well as prostate cancer development. The tight regula-
tion of this channel has also been attributed to the
TRMP7 gene and the Ca/Mg ratio has also been demon-
strated in clinical studies of PCa patients. However, what
remains largely unknown is the presence or absence of
this ratio imbalance in BPH patients. This study therefore
sought to examine retrospectively, the Ca/Mg balance in a
cohort of BPH patients before and after three (3) months
of treatment.
Methods
Study design and site
The study was a retrospective observational study. The
folders of 30 BPH patients under medical supervision
who had opted for the use of a phytotherapeutic drug
from the ethanolic root extract of Croton membranaceus
capsules (20 mg t.i.d.) for a period of 3 months at the
Ghana Police Hospital Urology Clinic were examined.
Frozen archival blood samples were selected and exam-
ined based on patients who chose this form of therapy
which had just been introduced between January 2013
and December 2014. The Ghana Police Hospital is one
of the 11 centers in the country approved by the Minis-
try of Health to administer plant medicine. Thirty (30)
other control subjects within the age group who were di-
agnosed negative for BPH within the study period were
also used.
Ethical issues
The project was approved by the Ethics and Protocol
Review Committee of the School of Biomedical and Al-
lied Health Sciences with Ethics number SAHS-ET/
SAHS/PSM/ML/09/AA/26A/2012-2013. Furthermore,
approval was sought from the Police Hospital adminis-
tration. Informed consent was also sought from all par-
ticipants whose information and samples were used. The
study complied with the Helsinki Declaration of 1964,
with revision in October 2008.
Blood samples
A previous study was undertaken by this same group of
researchers that demonstrated the efficacy of Croton
membranaceus for BPH [16]. The rest of the samples
were achieved for this study. The ethics approval of the
previous study covered the present study. Archival blood
samples from that previous study were selected and ex-
amined based on patients who chose this form of drug
therapy (phytotherapy). Samples of patients who re-
ported to the Urology Department between January
2013 and December 2014 and opted for the photothera-
peutic treatment were used. All blood samples for the
PSA test as requested by the urologist at that time were
taken between 8 am and 12 pm. Blood samples (sera)
were then stored in the -20 °C freezer. These samples
were retrieved in January 2016 for the present study
from the Biochemistry Laboratory freezer and analyzed
for PSA, serum Ca, Mg, P, PTH, vitamin D, renal func-
tion (and albumin for calcium correction). The afore-
mentioned assays were analyzed for single samples [con-
trol (C)] whilst test cases had analysis done for “before
treatment” (BT) and “after treatment” (AT) samples.
Phytotherapeutic drug trace element (TE) analysis
Twenty (20) trace elements of the phytotherapeutic drug
[arsenic (As), chloride (Cl), cobalt (Co), chromium (Cr),
copper (Cu), cadmium (Cd), mercury (Hg), lead (Pb),
nickel (Ni), iron (Fe), manganese (Mn), iodine (I), van-
adium (V), aluminum (Al), magnesium (Mg), selenium
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(Se), potassium (K), sodium (Na), calcium (Ca), and zinc
(Zn)] were also examined by neutron activation analysis.
Biochemical assays
PSA
Total PSA (TPSA) was performed using AccuBind total
PSA ELISA kits purchased from MonoBind Inc. (Califor-
nia, USA) according to the manufacturer’s instructions.
The ELISA plate was coated with highly specific mono-
clonal anti-PSA antibodies. In brief, 25 μl of samples to-
gether with standards were aliquoted into designated
wells and incubated with 100 μl antibody-HRP enzyme
conjugate at room temperature for 30 min. The plate
was then washed with a wash buffer after which 100 μl
of 3,3′,5,5′- tetramethylbenzidine (TMB)/hydrogen per-
oxide (substrate) was then added to react with the HRP.
After 15 min incubation, the reaction was terminated by
the addition of concentrated H2SO4. The final chromo-
gen was read at 450 nm on a BioTek plate reader (VT,
USA). TPSA was calculated from the calibration curve.
Parathyroid hormone (PTH) and vitamin D
PTH and vitamin D levels were estimated by ELISA tech-
niques using Sunlong Biotech Co. Ltd. (Hangzhou, China).
In brief, microtiter plates coated with PTH and vitamin D
antibodies were used. PTH and vitamin D from the blood
samples reacted with the antibodies immobilized on the
plate and the immunogen was further developed using a
second antibody-horseradish peroxidase conjugate. The
final chromogen was read at 450 nm.
Calcium/Magnesium/Phosphorous determination
Serum concentration of Ca, Mg, phosphorous (P), urea,
creatinine, sodium, potassium and albumin were deter-
mined by standard analytic methods on the Mindray BS
300 Chemistry analyzer (New York, USA) using com-
mercial kits from Elitech (France). All assays were per-
formed with standards and controls.
Trace element analysis of phytotherapeutic drug
It has been suggested that Mg and other trace elements
(TE) supplementation may play a role in shrinking an
enlarged prostate. To this end, TE analysis was per-
formed to ascertain whether the phytotherapeutic drug
could possible play the role of a TE supplement. In brief,
TE were determined by neutron activation analysis
(NAA) at the Ghana Atomic Energy Commission. Sam-
ples of de-capsulated extract (Croton membranaceus)
alongside international standards and controls were irra-
diated in the Ghana Research Reactor – 1 (GHARR-1)
operating at 15 KW and a thermal flux of 5 × 1011 n.cm
-2. S-1. Samples were irradiated for 5 min followed by
10 min of counting. The radioactivity measurement of
induced radionuclide was performed by a PC interfaced
with the γ-ray spectrometric equipment. The following
trace elements were analyzed: As, Cl, Co, Cr, Cu, Cd,
Hg, Pb, Ni, Fe, Mn, I, V, Al, Mg, Se, K, Na, Ca, and Zn
Statistical analysis
IBM SPSS statistics for Windows, Version 21.0
(Armonk, NY: IBM Corporation) and Microsoft Excel
2013 were used for the statistical analysis. Data was pre-
sented as mean ± standard deviation. Statistical analysis
between groups was determined by student’s t-test. Cat-
egorical variables were expressed as proportion. Correl-
ation analysis was performed with Pearson correlation
test. The level of significance was 0.050.
Results
Mean age for the control group was 56.14 ± 6.77 years and
that of the BPH group was 66.13 ± 11.04 years. Mean PSA
levels of controls, before treatment (BT) and after treat-
ment cases (AT) were 1.0 ± 0.64, 27.9 ± 19.0 and 16.2 ±
11.8 ng/mL, respectively. There was a significant differ-
ence before and after treatment (P = 0.002) (Table 1).
Serum Mg concentration was lower for BPH cases
(BT = 0.64 ± 0.18, AT = 0.77 ± 0.16 mmol/L), but higher
for the control group (0.8 ± 0.1 mmol/L). Control group
and BT group Mg differences were significant (p =
0.0001). Similarly, Mg BT and AT were different (p =
0.0031). Mg concentration differences were no more sig-
nificantly different after treatment compared to the con-
trol or BT (Table 1).
Serum Ca levels did not demonstrate significant differ-
ences between the three groups. However, slight increases
were observed in the test group before treatment. Al-
though the levels were marginal, levels dropped to that of
the control after treatment (C = 2.3 ± 0.24, AT = 2.29 ±
0.44 mmol/L) (Table 1). Similarly, changes in P showed a
slight increasing trend from C, BT to AT. However, in-
creases were not significant (Table 1).
The Ca/Mg ratios were as follows: C = 2.87 ± 0.48; BT
= 3.81 ± 1.12; AT = 2.96 ± 0.68. Significant differences
were observed between the C and BT (p = 0.0001) and
BT and AT (0.0001). However, the ratio after treatment
and that of the control group no longer showed signifi-
cant differences (Table 1). Parathyroid hormone and
vitamin D as well as the renal function test did not show
any statistical difference (Tables 2 and 3, respectively).
There was a positive correlation between Ca and Mg
before treatment (r = 0.391; p = .033). However, this cor-
relation did not exist after treatment with levels similar
to the control group. Similarly, there was a positive cor-
relation between Mg and P before treatment (r = 0.398;
p = .029). Correlation no longer existed after treatment
with levels similar to the control group (Table 4).
Between Ca and P a positive correlation existed in the
disease state (Table 4). A phosphate Ca/Mg correlation
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was highly significant and inversely correlated in the con-
trol group (r = -0.884). This correlation existed moderately
in the test groups (Table 4). Calcium Ca/Mg ratio showed
a strong positive correlation in the control group (r =
0.700; p < .001). This correlation also existed in the disease
groups to a moderate extent (Table 4). The magnesium
Ca/Mg ratio showed a strong inverse correlation in the
control group (r = -0.755; p < .001). However, the correl-
ation was moderate in the disease group (Table 4). No cor-
relation was observed between TPSA and Ca/Mg ratio.
The prevalence of hypomagnesemia in BPH patients
was 86.7% in tandem with a hypercalcemia of 36.7%. Both
levels were approximately 5 and 4 times, respectively, that
of the control group. After treatment Mg-Ca levels were
almost that of the control group (Table 5). The prevalence
of the Ca/Mg imbalance using the upper limit of the con-
trol group [2.87 (2.39–3.35)] was 80% before treatment
(BT). This was reduced to 13.3% after treatment (AT).
The control group prevalence was 3.3% (Table 5).
Out of the 30 cases only 18 had their prostate volumes
on record. There was no correlation between the Ca/Mg
ratio and the prostate volume (Table 6).
To ascertain whether the Ca/Mg ratio that was appar-
ently corrected after treatment could be related to TE in
the phytotherapeutic drug, TE analysis was conducted.
From Table 7, Ca was of the highest concentration
(58446 mg/kg dry wt.); this was followed by K
(7452 mg/Kg dry wt.). The third highest was Mg
(3239 mg/kg dry wt.). Traditional antioxidants that have
been suggested to aid prostate treatment were very low
(Zn = 2.992 and Se = 0.16 mg/Kg dry wt.). Other toxic
ultra-trace elements such as Hg, As and Pb were of neg-
ligible quantities (Table 7).
Discussion
Minerals are naturally occurring elements found in the
earth with a characteristic crystalline structure and
chemical composition. Dietary minerals are inorganic
nutrients and are usually required in small amounts
of 1-2500 mg per day [17]. The inorganic nature of
these micro-nutrients differentiates them from the
other micro-molecules that are organic such as vita-
mins [18]. Traditionally, minerals are grouped into
two categories; macro (major) - and micro – (trace)
elements. A third category is the ultra-trace element
[19]. Whereas the macro - and micro - elements are
required in amounts > 100 mg/day and < 20 mg/day,
respectively, ultra-trace elements are required in the
region of 1 mg/day. Arsenic, bromine, boron, chro-
mium, cadmium, fluorine, lead, lithium, molybdenum,
nickel, selenium, silicon, tin and vanadium fit into
this category [19].
The importance of trace elements to health cannot
be under-estimated even though they are required in
minute quantities. At least 17 known essential ele-
ments and many others are needed for good health
and inadequate amounts of trace elements such as so-
dium, potassium, magnesium and calcium have a link
to the development of diseases [20]. Trace metal con-
centrations including Cd, Ni, Zn, Cu, Fe, Mg, and Ca
in both malignant and benign prostate samples have
been determined [2].
Imbalance in trace elements such as P, Ca, Mg that are
essential to normal human homeostasis, results in a
number of clinical complications including prostate can-
cer. Suggested processes implicated in the progression of
prostate disorders are from oxidative stress, to cellular
senescence [21, 22]. Mineral metabolism which includes
Ca, Mg and P occurs through three main target organs:
the bone, intestine and kidney. The homeostatic control
of these minerals is primarily facilitated by the parathy-
roid hormone and vitamin D.. However, there is still a
gap in our understanding regarding the relationship be-
tween trace element functions and initiation as well as
Table 1 Table showing PSA differences as well as Ca, Mg and PO4 levels of the control and BPH group
Mean ± SD Control group Mean ± SD Treatment group (Before –BT) Mean ± SD Treatment group (After – AT) p-value
PSA ng/mL 1.0 ± 0.64 27.9 ± 19.0 b 16.2 ± 11.8 b 0.002
Mg mmol/L 0.8 ± 0.1 a 0.64 ± 0.18 a,b 0.77 ± 0.16 b 0.0001a/0.0031 b
Ca mmol/L 2.30 ± 0.24 2.44 ± 0.85 2.29 ± 0.44 NS
PO4 mmol/L 1.4 ± 0.3 1.53 ± 0.35 1.63 ± 0.32 NS
Ca/Mg 2.87 ± 0.48a 3.81 ± 1.12 a,b 2.96 ± 0.68 b 0.0001a/0.0001 b
a Indicates comparison between control and test groups; whist b indicates comparison between Before Treatment levels and After Treatment. NS not
significant (n = 30)
Table 2 Parathyroid hormone (PTH) and Vitamin D levels of the control and BPH group
Parameter Mean ± SD Control group Mean ± SD Treatment group (Before - BT) Mean ± SD Treatment group (After - AT) P-value
PTH (pg/mL) 45.26 ± 19.72 50.68 ± 18.87 49.36 ± 17.61 NS
Vitamin D (ng/mL) 30.60 ± 18.98 28.55 ± 8.70 32.06 ± 12.76 NS
n = 30; NS not significant
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progression and inhibition of the carcinogenic process in
the prostatic gland [23, 24].
In this study Mg levels were found to be significantly
lower in patients with BPH compared to the control
group. Mg has an effect on a variety of cell membranes
through a process involving Ca channels and ion trans-
port mechanisms. Mg is therefore responsible for the
maintenance of the trans-membrane gradients of sodium
and potassium [25].
On the other hand Ca was significantly higher in pa-
tients with BPH compared to the controls. Serum Ca
was shown not to be associated with the risk of prostate
cancer [26]. Contrary to this, a weak negative association
has been shown between serum Ca and the incidence of
fatal prostate cancer in Swedish men [27]. Furthermore,
the association between serum Ca levels and aggressive
lesions or fatal prostate cancer has been observed in
some studies [28]. It has been previously hypothesized
that high serum Ca or PTH increase, is a risk factor for
fatal prostate cancer [29]. However, Ca levels in BPH pa-
tients have not been previously demonstrated to be asso-
ciated with the development of this condition.
This study demonstrated a moderate positive associ-
ation between Ca and Mg as well as Mg and P in the
disease state. The association disappeared after treat-
ment and was similar to the status of the controls. In-
deed Ca and Mg are both reabsorbed at the loop of
Henle. The correlation was perhaps an attempt to create
the necessary balance by increasing Mg reabsorption. Al-
though Ca may be reabsorbed alongside Mg, both may
not be to the same extent and perhaps Ca reabsorption
is truncated when Mg is adequately reabsorbed. It has
been shown that Ca reabsorption is not altered in Mg
deficiency; however, elevations of extracellular Mg re-
sults in a specific inhibition of Ca reabsorption within
the loop of Henle [30]. This positive correlation disap-
peared after treatment when the Ca/Mg ratio had
normalized.
The P and Mg positive correlation may be due to P
co-absorption with Mg as a compensatory mechanism.
The P reabsorption may not be PTH controlled but a re-
duction in the amount of titrable P at the distal convo-
luted tubules. It is postulated that an abnormal
homeostasis occurs. It has been demonstrated that in
parathyroidectomized rats, Mg depletion was equally as-
sociated with P depletion. However, one study has sug-
gested that the overall control of renal Mg reabsorption
occurs within the loop of Henle and that the proximal
tubule reabsorbs a constant fraction of the filtered load
despite variations in body Mg status [30]. In that study,
proximal Mg reabsorption remained unchanged at 15%
of the filtered load and was unaffected by Mg deficiency
or acute Mg repletion. However, distal tubular Mg re-
absorption was limited during depletion and increased
to a similar extent in control and deficient rats with en-
hanced Mg delivery [30]. The mechanism of P reabsorp-
tion under such circumstances of Mg reabsorption is
not clearly understood.
Hypomagesemia has been reported in a number of dis-
ease conditions diarrhea, vomiting and gastrointestinal
Table 3 Renal function tests of the control and BPH group
Parameter Mean ± SD Control group Mean ± SD Treatment group (Before- BT) Mean ± SD Treatment group (After - AT) P-value
Sodium (mmol/l) 140.6 ± 3.5 142.8 ± 6.6 142.2 ± 6.6 NS
Potassium (mmol/l) 4.2 ± 0.5 4.3 ± 0.6 4.3 ± 0.6 NS
Urea (mmol/l) 4.0 ± 2.3 4.3 ± 1.4 4.4 ± 1.3 NS
Creatinine (μmol/l) 89.3 ± 23.4 105.9 ± 26.5 106.0 ± 26.2 NS
N = 30; NS not significant
Table 4 Pearson’s Correlation analysis
Correlation Parameters Control Group BPH Group Before Treatment BPH Group After Treatment
Parameter A Parameter B
r p-value r p-value r p-value
Ca Mg - .391 a 0.033 -
Mg P - .398 a 0.029
Ca P - .529 b 0.003 .523 b 0.003
P Ca/P -.884 b < .001 -.559 b 0.001 -.560 b 0.001
Ca Ca/Mg .700 b < .001 .482 b 0.007 .501 b 0.005
Mg Ca/Mg -.755 b < .001 -.493 b 0.001 -.473 b 0.008
TPSA Ca/Mg - - -
a Correlation is significant at the 0.05 level (2-tailed)
b Correlation is significant at the 0.01 level (2-tailed)
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fistulas. A prevalence of 11% was reported when 621
hospital patients (in the USA) were randomly selected
compared to 2.5% in the control group made up of 341
hospital staff [31]. Other disease conditions such as mal-
absorption, diarrhea, hypertension, cognitive heart fail-
ure, coronary artery disease among others have all been
reported to be associated with hypomagnesaemia [32, 33].
Hypomagnesaemia was present in 86.7% of the patients
diagnosed with BPH. The control group had a hypomeg-
nesemia prevalence of 16.7% which is comparable to a
prevalence of 14.5% among 16,000 apparently normal
Germans studied [34]. The prevalence for 11,000 white
urban Americans (45 to 64 years) was between 2.5 and
5% depending on the lower limit used. Twice this preva-
lence was found in African Americans [35]. The 80%
prevalence of a high Ca/Mg ratio was reduced to 13.3%
after treatment, although this was still higher than the
3.3% prevalence found in the control group.
The phytotherapeutic drug that was administered
(made of Croton membranaceus) was analyzed for its
trace element content. It was noted that the extract was
high in Ca, followed by potassium and Mg. Indeed the
Ca level was 18 times that of Mg; nevertheless Ca ab-
sorption is always tightly regulated. Although the serum
Mg level was significantly low while the Ca/Mg ratio
was significant high before treatment, the Mg level sig-
nificantly increased to that of the controls and the Ca/
Mg ratio significantly reduced to the level of the controls
after treatment.
In several studies investigating the relationship be-
tween Ca intake and the risk of developing aggressive or
clinically relevant prostate cancers as well as the rela-
tionship between prostate disorders, PTH and vitamin D
have both generated null [26, 36] and positive results
[37]. Blood Ca levels are tightly regulated and only mod-
erately affected by dietary intake of Ca and absorption
rates [38]. Thus, one possible explanation for the incon-
sistencies across study populations is that dietary intake
measures of Ca may not accurately reflect the blood Ca
concentrations to which prostate tissues are exposed [6].
Whether the phytotherapeutic drug’s trace element
levels contributed to the correction of the Ca/Mg imbal-
ance in the BPH group is a mechanism to consider or
whether the corrected imbalance is a result of some
other mechanism(s), is debatable. The former is very un-
likely considering the RDA for Ca and Mg and the over-
all 60 mg intake of the plant extract drug which is far
below the RDA. Nevertheless, the imbalance and its as-
sociation with the Ca channels remain plausible.
Ca channels and the Ca/Mg ratio is a developing area
of focus. The Ca/Mg ratio in this study was significantly
raised in the BPH group compared to the control group.
Studies have shown that inadequate Mg levels, relative
to Ca levels (i.e. high Ca/Mg ratio) are associated with
greater risk of prostate disorders. Among high-grade
prostate cancer cases compared to controls, serum Mg
levels were significantly lower, while the Ca/Mg ratio
was significantly higher. An elevated Ca/Mg ratio was
therefore associated with an increased risk of high-grade
prostate cancer and elevated Mg was significantly associ-
ated with a lower risk [6]. However, only one or two
studies seem to have examined this phenomenon in
BPH patients.
It has been recently demonstrated that a high Ca/Mg ratio
is pro-inflammatory and Mg increase reverses this imbal-
ance through gate-keeping activities of TRPM6/7 gene in an
apoptotic drive. The apoptotic mechanism of this phytother-
apeutic drug made of Croton membraneus on BPH-1 cells
have recently been demonstrated [39]. Therefore, the
present Ca/Mg ratio correction is still in keeping with the
apoptotic mechanism established previously by [39].
The PSA levels were also reduced significantly after
treatment and symptoms improved significantly by the
International Prostate Symptoms Score (IPSS) assess-
ment as published elsewhere [16]. The correlation be-
tween Ca/Mg and PSA levels were not established, just
as the correlation between prostate volume and the Ca/
Mg ratio. Whether this ratio pertains to the initiation or
progression of the disease remains unknown and re-
quires further studies.
Table 5 Prevalence of low Mg and high Ca levels as well as the Ca/Mg ratio imbalance
Prevalence levels of Mg and Ca Control group Treatment group (Before – BT) Treatment group (After – AT)
Prevalence of low Mg (%) 16.7 86.7 13.3
Prevalence of high Ca (%) 10.0 36.7 13.0
Prevalence of Ca/Mg ratio imbalance (%) 3.33 80.0 13.3
n = 30
Table 6 Calcium Magnesium levels and the corresponding prostate volumes of individuals whose data could be retrieved
Patient ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Ca/Mg ratio 3.11 4.02 4.09 3.82 3.41 3.69 3.41 4.09 3.48 3.15 4.04 3.81 3.60 5.17 3.08 3.46 4.33 5.25
Prostate vol (cm-3) 104 15.2 44.4 115 45.8 13.4 131 79.8 137 47.7 94.5 30.1 61 149 49.9 198 150 105
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Conclusion
Ca/Mg ratio imbalance is associated with BPH similar to
observations in PCa. This has previously not been dem-
onstrated. The imbalance was corrected after treatment.
Although apoptosis is suspected to be one of the mecha-
nisms for the action of this pytotherapeutic drug, the ac-
tual mechanism is yet to be elucidated.
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